Nos études

393 000 patients dans notre étude réalisée à partir des bases du SNDS.

Estimating the prevalence of rheumatoid arthritis (RA) in France using care pathways in the National Health Data System (SNDS): opportunities and limitations – PREST study.

Communications congrès :
Gauxjoux-Viala C. et al., communication orale : abstract n°000087, SFR 2024
Gauxjoux-Viala C. et al., poster 0147, ACR 2025

3 772 internautes dans notre projet d’infodémiologie.

Rheumatoid Arthritis: patient’s voice first! An original approach based on infodemiology using social media content – Results from the PRIMA study.

Communications congrès :
Gauxjoux-Viala C. et al., poster 2149, ACR 2024
Sellam J. et al., communication orale : abstract n°000034, SFR 2024

Methotrexate maintenance one year after initiation of a first targeted therapy: results if the prospetive STARTEGE 2 study.

Communications congrès :
Gauxjoux-Viala C. et al., poster PE, Lu-071, SFR 2021
Gauxjoux-Viala C. et al., poster PC42, SFR 2022
Gauxjoux-Viala C. et al., poster P0S0698, Annals of the Rheumatic Disease, EULAR 2022
Gauxjoux-Viala C. et al., poster P0S0635, Annals of the Rheumatic Disease, EULAR 2022
Gauxjoux-Viala C. et al., communication orale : abstract n°000288, SFR 2023
Gauxjoux-Viala C. et al., poster 1366, ACR 2024
Gauxjoux-Viala C. et al., poster 0360, ACR 2024

Benefits of switch from oral to subcutaneous route on adherence to methotrexate in patients with rheumatoid arthritis in real life setting.

Senbel E. et al., Patient Prefer Adherence., 2021, April 14 (15:751-760)

MTX optimization or adding bDMARD equally improve disease activity in rheumatoid arthritis: results from the prospective study STRATEGE

Gaujoux-Viala C et al., Rheumatology (Oxford). 2021 Dec 24;61(1):270-280.

Use of auto-injector for methotrexate subcutaneoous self-injections: high satisfaction level and good compliance in SELF-I study, a randomized, open-label, parallel group study.

Saraux A. et al., Rheumatol Ther., 2019, March 6 (6(1):47-60)

Evaluation of usability and acceptance of a new autoinjector intended for methotrexate subcutaneous self-administration in the management of rheumatoid arthritis.

Hudry C. et al., Rheumatol Ther., 2017, June 4 (1:183-194)